Alicia Zhou/LinkedIn
Jun 5, 2025, 09:01
Alicia Zhou: Introducing the 2025 CRI Cancer Immunotherapy Insights + Impact Report
Alicia Zhou, CEO at Cancer Research Institute, shared a post on LinkedIn:
“I’m so thrilled to share the release of CRI’s inaugural Cancer Immunotherapy Insights + Impact report – our comprehensive, data-driven look at the evolution of cancer immunotherapy from 2011 through 2024.
This report maps more than 150 FDA approvals, highlights real-world adoption trends, and captures the therapeutic innovations reshaping the field – from the first-ever TIL and TCR approvals in solid tumors to new subcutaneous formulations that are making treatment more accessible.
It’s designed for anyone working to move immunotherapy forward: scientists, regulators, investors, and clinicians alike.”
More posts featuring Alicia Zhou.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 5, 2025, 08:47
Jun 5, 2025, 07:54